20/20 Biolabs

Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines: revenue was $0.73M vs. $0.64M expected, and gross margin expanded to 41.7% vs. 35.0% expected. The OneTest™ product line drove 95.3% of total sales, reflecting a successful mix shift toward higher-margin AI blood tests. Despite the revenue beat, net loss widened YoY to -$1.51M due to one-time Nasdaq listing costs and R&D investment, though GAAP EPS of -$0.26 was significantly below the -$0.12 consensus due to a ~124% YoY increase in share count.